Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KESTREL: Durvalumab +/- Tremelimumab in 1st-line Recurrent/Metastatic SCCHN
NCT02551159Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Primary completion
- Jul 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of durvalumab in squamous cell carcinoma of the head and neck (HNSCC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Overall Survival at 4 years and Overall Survival Median Duration at 4 years. Started Oct 2015; status: completed.
02
Drugs
durvalumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02551159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02551159.